Ranibizumab-nuna - Biologic Drug Details

Summary for ranibizumab-nuna

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2

Pharmacology for ranibizumab-nuna

Mechanism of Action	Vascular Endothelial Growth Factor Inhibitors
Established Pharmacologic Class	Vascular Endothelial Growth Factor Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ranibizumab-nuna Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ranibizumab-nuna Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ranibizumab-nuna Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Ranibizumab-nuna

Last updated: February 14, 2026

Overview:
Ranibizumab-nuna is a biosimilar to Lucentis (ranibizumab), approved for treating neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema, and other ocular conditions. As a biosimilar, it aims to reduce treatment costs and increase access, impacting both the market landscape and the revenue streams of innovator products.

---

Regulatory Status and Market Access
Ranibizumab-nuna gained regulatory approval in multiple jurisdictions, including South Korea, where it is manufactured by Celltrion. Its approval for indications equivalent to the reference biologic Lucentis enables its commercialization across ophthalmology markets.

• South Korea (approved in 2021)
• European Union (application submitted)
• Latin America and Asia (regional launches ongoing)

The approval timeline indicates an aggressive market entry to capitalize on biosimilar policies, especially in regions with cost containment initiatives.

---

Market Size and Penetration

Parameter	Data	Source
Global AMD market (2022)	$8.7 billion	Fortune Business Insights[1]
Market share of biosimilars (2022)	6% of ophthalmology biologics	IQVIA[2]
Estimated biosimilar ophthalmology revenue (2023)	$200 million worldwide	EvaluatePharma[3]

Ranibizumab-nuna aims to capture a significant portion of the approximately $8.7 billion AMD market by leveraging price reductions (up to 40-50% savings over Lucentis) and expanding access in price-sensitive regions.

Market entry assumptions

• Initial penetration: 10-15% within two years post-launch in South Korea.
• Rapid expansion expected in Europe, especially in countries with biosimilar policies incentivizing substitution.

---

Pricing and Reimbursement Dynamics
Pricing varies by region. South Korea’s National Health Insurance System (NHIS) sets reimbursement levels, significantly impacting revenue projections.

• South Korea: Biosimilars like ranibizumab-nuna priced at 55-65% of Lucentis.
• Europe: Price discounts 30-50%, with some countries imposing tender-based procurement, favoring biosimilar adoption.
• U.S.: No biosimilar approved yet, but pending FDA review increases market prospects.

Reimbursement policies and tendering processes influence adoption rates. Biosimilar inclusion in formularies leads to faster uptake, especially where government agencies promote cost savings.

---

Competitive Landscape

Competitors	Products	Market Share (2022)	Key Features
Lucentis (Roche)	Ranibizumab	Approx. 60% in AMD (global)	Established efficacy, high brand loyalty
Beovu (Novartis)	Brolucizumab	20-25%	Alternative longer-lasting injection schedule
Eyelea (Eli Lilly)	Aflibercept	15-20%	Broader indication profile

Biosimilar entrants, including ranibizumab-nuna, face competition primarily from Lucentis's brand dominance and existing patents protecting certain markets until 2024-2027.

---

Financial Trajectory

Revenue Projections (2023-2027):

• 2023: $50 million, targeting initial adoption in South Korea and parts of Europe
• 2024: $180 million, driven by expanded regional access and formulary inclusion
• 2025: $350 million, capturing 15-20% of AMD biosimilar segment globally
• 2026: $500 million, as market penetration stabilizes and new regions open
• 2027: $700 million, with increased competition and broader indications

These projections assume aggressive market entry, favorable reimbursement policies, and competitive pricing strategies.

Cost considerations include manufacturing, regulatory compliance, marketing, and distribution. Celltrion’s low-cost manufacturing in Asia allows for high-margin pricing at lower consumer prices, improving profitability.

---

Regulatory and Policy Influences

• Biosimilar policies favoring substitution and tendering in Europe and Asia accelerate biosimilar adoption.
• Patent expiration of Lucentis’s core patents in 2024-2027 opens further market opportunities.
• Physician and patient acceptance, driven by efficacy equivalence and perceived safety, remains crucial.

---

Risks and Challenges

• Slow adoption due to brand loyalty for Lucentis.
• Regulatory hurdles and regional policy shifts.
• Potential patent litigations affecting market entry timing.
• Competitive innovations in ophthalmologic biologics.

---

Key Takeaways

• Ranibizumab-nuna is positioned to enter a sizable AMD market, driven by biosimilar price advantages.
• Adoption hinges on regional reimbursement policies, tender processes, and physician acceptance.
• Revenue estimates show rapid growth from 2023 through 2027, contingent on market dynamics.
• Competition from Lucentis and other biologics remains a barrier, but patent expirations and policy shifts offer growth opportunities.
• Cost advantages fostered by Celltrion bolster margin potential and market penetration.

---

FAQs

What is the competitive advantage of ranibizumab-nuna?
Its lower price point compared to Lucentis, combined with manufacturing efficiencies and regional market access, enhances adoption prospects.

How does biosimilar regulation influence ranibizumab-nuna’s market trajectory?
Regulatory approval facilitates market access; policies promoting substitution or tendering accelerate biosimilar uptake.

Isranibizumab-nuna's revenue projected to surpass Lucentis?
Not immediately; biosimilar revenue growth depends on market penetration, reimbursement policies, and existing brand loyalty.

How does patent expiry affect the biosimilar market?
Expiration of Lucentis patents in key territories in 2024-2027 allows biosimilar manufacturers, including Celltrion, to expand globally.

What are the primary risks for ranibizumab-nuna’s success?
Market resistance due to brand loyalty, regulatory delays, and competitive product launches.

---

Citations
[1] Fortune Business Insights. "Age-Related Macular Degeneration Market Size." 2022.
[2] IQVIA. "Global Biosimilar Market Report." 2022.
[3] EvaluatePharma. "Biosimilars & Biologics Revenue Projections." 2022.